Modeling Long-Term Progression-Free Survival in Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone.

Projected long-term progression-free survival is substantially longer with DVRd than VRd in newly diagnosed multiple myeloma, with best-fit median PFS 205 vs 87 months in transplant-eligible patients.

• Why it matters: Trial follow-up is limited for long-term outcomes, so decision-making needs extrapolated survival estimates to compare DVRd and VRd over extended horizons.
• What they did: Using UK NICE extrapolation guidance, seven parametric distributions were fitted to progression-free survival data from PERSEUS (TE) and CEPHEUS (TIE subgroup) to project median PFS.
• The result: In TE, DVRd median PFS was 205 months (17.1 years) versus 87 months (7.3 years), and in TIE it was 100 months (8.3 years) versus 53 months (4.4 years), with longer projections across all seven distributions.

AI summary of the abstract · may contain errors · not medical advice · read the paper.